Search - tctmd.com

Displaying 321 - 340 of 400

Sort: Relevancy | Date

Presentation TCT 2014

Sudden Cardiac Death and Atrial Fibrillation in HCM

Presenter: John S. Douglas Jr, Sherif F. Nagueh, Howard C. Herrmann, Kishore J. Harjai

September 16, 2014

Presentation TCT 2014

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

Presenter: Vivian Lee

September 16, 2014

Presentation TCT 2014

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Presenter: Saibal Kar, Bushra S Rana, Jai-Wun Park, Vivian Lee

September 15, 2014

Presentation TCT 2014

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang

September 15, 2014

Presentation TCT 2014

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Georgios Christodoulidis

September 15, 2014

Presentation TCT 2014

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Michael D. Ezekowitz

September 15, 2014

Presentation TCT 2014

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Christopher B. Granger

September 15, 2014

Presentation TCT 2014

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson

September 15, 2014

Presentation TCT 2014

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Laura Mauri

September 15, 2014

Presentation TCT 2014

Current (and Future) Guidelines for Atrial Fibrillation Treatment

Presenter: Josep Rodés-Cabau, Brian K. Whisenant, David Hildick-Smith, Ted E. Feldman

September 15, 2014

Presentation TCT 2014

Stroke, Bleeding, and Risk Scores in Atrial Fibrillation

Presenter: Josep Rodés-Cabau, Brian K. Whisenant, David Hildick-Smith, Stefan C. Bertog

September 15, 2014

Presentation TCT 2014

Putting it All Together: Anticoagulants, Rhythm Control, and LAA Closure Which Therapy for Which Patient?

Presenter: Matthew J. Price, Shephal Doshi

September 15, 2014

Presentation TCT 2014

Shifting the Treatment Paradigm with LAA Closure: Efficacy, Complications, and Future Challenges

Presenter: Matthew J. Price

September 15, 2014

Presentation TCT 2014

The Triple Therapy Conundrum: Treatment of the PCI Patient with Atrial Fibrillation

Presenter: Matthew J. Price, C. Michael Gibson

September 15, 2014

Presentation TCT 2014

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Presenter: Matthew J. Price, Michael D. Ezekowitz

September 15, 2014

Presentation TCT 2014

Incidence, Significance, and Management of New-Onset Atrial Fibrillation After TAVR

Presenter: Josep Rodés-Cabau, Mathew Williams, Azeem Latib

September 14, 2014

Presentation TCT 2014

Can LAA Closure Become the New Standard for Stroke Prevention?

Presenter: Hilary Nierenberg, Julie Logan, Saibal Kar

September 14, 2014

Presentation TCT 2014

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

Presenter: Hilary Nierenberg, Julie Logan, Asma Hussaini

September 14, 2014

Presentation TCT 2014

The Electrophysiologists Approach to Managing Atrial Fibrillation

Presenter: Hilary Nierenberg, Julie Logan, Taya V. Glotzer

September 14, 2014

Presentation TCT 2014

Percutaneous Left Atrial Appendage Closure for Atrial Fibrillation: Where Are We Compared to New Drugs and Ablation

Presenter: Jose Luis Assad-Morell, Efrain Gaxiola, Matthew J. Price

September 13, 2014

Advertisement

Sudden Cardiac Death and Atrial Fibrillation in HCM

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Current (and Future) Guidelines for Atrial Fibrillation Treatment

Stroke, Bleeding, and Risk Scores in Atrial Fibrillation

Putting it All Together: Anticoagulants, Rhythm Control, and LAA Closure Which Therapy for Which Patient?

Shifting the Treatment Paradigm with LAA Closure: Efficacy, Complications, and Future Challenges

The Triple Therapy Conundrum: Treatment of the PCI Patient with Atrial Fibrillation

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Incidence, Significance, and Management of New-Onset Atrial Fibrillation After TAVR

Can LAA Closure Become the New Standard for Stroke Prevention?

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

The Electrophysiologists Approach to Managing Atrial Fibrillation

Percutaneous Left Atrial Appendage Closure for Atrial Fibrillation: Where Are We Compared to New Drugs and Ablation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content